Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 671

1.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.

Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

Curr Med Res Opin. 2008 Oct;24(10):2805-13. doi: 10.1185/03007990802336780 . Epub 2008 Aug 27.

PMID:
18755054
[PubMed - indexed for MEDLINE]
2.

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.

Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

Curr Med Res Opin. 2008 Sep;24(9):2587-95. doi: 10.1185/03007990802303525 . Epub 2008 Jul 31.

PMID:
18674407
[PubMed - indexed for MEDLINE]
3.

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.

Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

J Med Econ. 2009 Jun;12(2):124-35. doi: 10.3111/13696990903093537.

PMID:
19566483
[PubMed - indexed for MEDLINE]
4.

Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.

Khandker RK, Kruzikas DT, McLaughlin TP.

J Manag Care Pharm. 2008 Jun;14(5):426-41.

PMID:
18597572
[PubMed - indexed for MEDLINE]
Free Article
5.

Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.

Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.

Manag Care. 2012 Jan;21(1):49-58.

PMID:
22332457
[PubMed - indexed for MEDLINE]
Free Article
6.

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.

Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.

Pharmacoeconomics. 2008;26(11):969-81.

PMID:
18850765
[PubMed - indexed for MEDLINE]
7.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Ann Pharmacother. 2011 Apr;45(4):441-51. doi: 10.1345/aph.1P482. Epub 2011 Mar 17.

PMID:
21415162
[PubMed - indexed for MEDLINE]
8.

Escitalopram in the treatment of major depressive disorder: a meta-analysis.

Kennedy SH, Andersen HF, Thase ME.

Curr Med Res Opin. 2009 Jan;25(1):161-75. doi: 10.1185/03007990802622726 .

PMID:
19210149
[PubMed - indexed for MEDLINE]
9.

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.

Lam RW, Lönn SL, Despiégel N.

Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8.

PMID:
20357664
[PubMed - indexed for MEDLINE]
10.
11.

Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.

Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW.

J Manag Care Pharm. 2006 Jan-Feb;12(1):43-54.

PMID:
16420107
[PubMed - indexed for MEDLINE]
Free Article
12.

Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.

Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW.

Clin Ther. 2009 Mar;31(3):644-56. doi: 10.1016/j.clinthera.2009.03.012.

PMID:
19393855
[PubMed - indexed for MEDLINE]
13.

Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.

Monfared AA, Han D, Sheehy O, Bexton B, Lelorier J.

Curr Med Res Opin. 2006 Jan;22(1):83-94.

PMID:
16393434
[PubMed - indexed for MEDLINE]
14.

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.

Kongsakon R, Bunchapattanasakda C.

J Med Assoc Thai. 2008 Jul;91(7):1117-28.

PMID:
18839855
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.

Hemels ME, Kasper S, Walter E, Einarson TR.

Curr Med Res Opin. 2004 Jun;20(6):869-78.

PMID:
15200745
[PubMed - indexed for MEDLINE]
16.

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

Fernandez JL, Montgomery S, Francois C.

Pharmacoeconomics. 2005;23(2):155-67.

PMID:
15748090
[PubMed - indexed for MEDLINE]
17.
18.

Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.

Wade AG, Saragoussi D, Despiégel N, François C, Guelfucci F, Toumi M.

Curr Med Res Opin. 2010 May;26(5):1161-70. doi: 10.1185/03007991003738519.

PMID:
20297951
[PubMed - indexed for MEDLINE]
19.

Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.

Griffiths RI, Sullivan EM, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.

Pharmacoeconomics. 1999 May;15(5):495-505.

PMID:
10537966
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk